Aprea Therapeutics, Inc. (APRE)

NASDAQ: APRE · IEX Real-Time Price · USD

4.000

+0.180 (4.71%)

Jul 22, 2024, 9:30 AM EDT - Market open

Aprea Therapeutics Employees

Aprea Therapeutics had 7 employees as of December 31, 2023. The number of employees decreased by 2 or -22.22% compared to the previous year.

Employees

7

Change (1Y)

-2

Growth (1Y)

-22.22%

Revenue / Employee

$137,686

Profits / Employee

-$1,816,708

Market Cap

21.72M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	7	-2	-22.22%
Dec 31, 2022	9	-	-

Related Stocks

Company Name	Employees
ImmunoPrecise Antibodies	102
Ekso Bionics Holdings	72
Inspira Technologies Oxy B.H.N.	42
Viracta Therapeutics	40
Gain Therapeutics	32
OneMedNet	20
Minerva Neurosciences	9

Employee Rankings

APRE News

4 weeks ago - Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 - GlobeNewsWire
5 weeks ago - Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 - GlobeNewsWire
7 weeks ago - Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial - GlobeNewsWire
2 months ago - Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
2 months ago - Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
2 months ago - Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D. - GlobeNewsWire
3 months ago - Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 - GlobeNewsWire
4 months ago - Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update - GlobeNewsWire